Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Mirvetuximab Soravtansine→

Mirvetuximab Soravtansine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1453084-37-1
Molecular formula
Not available
Molecular weight
Not available
Drug class
Folate receptor alpha (FRα)-directed antibody–drug conjugatemicrotubule inhibitor payload
Mechanism of action
The antibody binds FRα on tumour cells and is internalised. Intracellular cleavage releases DM4, a maytansinoid microtubule inhibitor that disrupts the microtubule network, causing cell-cycle arrest and apoptotic cell death.
Indications / reported uses
  • Treatment of adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian-tube or primary peritoneal cancer after one to three prior systemic treatment regimens, using an FDA-authorised FRα test; see current label for eligibility and ocular monitoring

Sources: US DailyMed — ELAHERE (mirvetuximab soravtansine-gynx) · NICE — Mirvetuximab soravtansine guidance, 24 June 2026 · Health Canada — ELAHERE product status · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Folate receptor alpha (FRα)-directed antibody–drug conjugate; microtubule inhibitor payload

Mechanism of action

The antibody binds FRα on tumour cells and is internalised. Intracellular cleavage releases DM4, a maytansinoid microtubule inhibitor that disrupts the microtubule network, causing cell-cycle arrest and apoptotic cell death.

General use cases

  • Treatment of adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian-tube or primary peritoneal cancer after one to three prior systemic treatment regimens, using an FDA-authorised FRα test; see current label for eligibility and ocular monitoring

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Mirvetuximab Soravtansine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mirvetuximab Soravtansine Permitted Daily Exposure (PDE) report (the Mirvetuximab Soravtansine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mirvetuximab Soravtansine Occupational Exposure Limit (OEL) report (the Mirvetuximab Soravtansine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.